The role of interleukin-2 in the treatment of cancer patients:
Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcino...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Dordrecht
Springer Netherlands
1993
|
| Subjects: | |
| Online Access: | UBR01 Volltext |
| Summary: | Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future |
| Physical Description: | 1 Online-Ressource (X, 191 p) |
| ISBN: | 9789401117531 |
| DOI: | 10.1007/978-94-011-1753-1 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145148 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1993 |||| o||u| ||||||eng d | ||
| 020 | |a 9789401117531 |9 978-94-011-1753-1 | ||
| 024 | 7 | |a 10.1007/978-94-011-1753-1 |2 doi | |
| 035 | |a (ZDB-2-SME)978-94-011-1753-1 | ||
| 035 | |a (OCoLC)1119086197 | ||
| 035 | |a (DE-599)BVBBV046145148 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a The role of interleukin-2 in the treatment of cancer patients |c edited by John Wagstaff |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 1993 | |
| 300 | |a 1 Online-Ressource (X, 191 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Immunology | |
| 650 | 0 | 7 | |a Interleukin 2 |0 (DE-588)4162018-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | 2 | |a Interleukin 2 |0 (DE-588)4162018-5 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Wagstaff, John |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792321644 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401117548 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401047692 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-94-011-1753-1 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525333 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-94-011-1753-1 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1804180481450704896 |
|---|---|
| any_adam_object | |
| author2 | Wagstaff, John |
| author2_role | edt |
| author2_variant | j w jw |
| author_facet | Wagstaff, John |
| building | Verbundindex |
| bvnumber | BV046145148 |
| classification_rvk | XH 3200 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-94-011-1753-1 (OCoLC)1119086197 (DE-599)BVBBV046145148 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-94-011-1753-1 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02674nmm a2200541zc 4500</leader><controlfield tag="001">BV046145148</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1993 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789401117531</subfield><subfield code="9">978-94-011-1753-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-94-011-1753-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-94-011-1753-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119086197</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145148</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The role of interleukin-2 in the treatment of cancer patients</subfield><subfield code="c">edited by John Wagstaff</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 191 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Interleukin 2</subfield><subfield code="0">(DE-588)4162018-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Interleukin 2</subfield><subfield code="0">(DE-588)4162018-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wagstaff, John</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792321644</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401117548</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401047692</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-94-011-1753-1</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525333</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-94-011-1753-1</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145148 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:27Z |
| institution | BVB |
| isbn | 9789401117531 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525333 |
| oclc_num | 1119086197 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 191 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Springer Netherlands |
| record_format | marc |
| spelling | The role of interleukin-2 in the treatment of cancer patients edited by John Wagstaff Dordrecht Springer Netherlands 1993 1 Online-Ressource (X, 191 p) txt rdacontent c rdamedia cr rdacarrier Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future Oncology Immunology Oncology Interleukin 2 (DE-588)4162018-5 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Therapie (DE-588)4059798-2 s Interleukin 2 (DE-588)4162018-5 s 1\p DE-604 Wagstaff, John edt Erscheint auch als Druck-Ausgabe 9780792321644 Erscheint auch als Druck-Ausgabe 9789401117548 Erscheint auch als Druck-Ausgabe 9789401047692 https://doi.org/10.1007/978-94-011-1753-1 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | The role of interleukin-2 in the treatment of cancer patients Oncology Immunology Oncology Interleukin 2 (DE-588)4162018-5 gnd Therapie (DE-588)4059798-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4162018-5 (DE-588)4059798-2 (DE-588)4073781-0 |
| title | The role of interleukin-2 in the treatment of cancer patients |
| title_auth | The role of interleukin-2 in the treatment of cancer patients |
| title_exact_search | The role of interleukin-2 in the treatment of cancer patients |
| title_full | The role of interleukin-2 in the treatment of cancer patients edited by John Wagstaff |
| title_fullStr | The role of interleukin-2 in the treatment of cancer patients edited by John Wagstaff |
| title_full_unstemmed | The role of interleukin-2 in the treatment of cancer patients edited by John Wagstaff |
| title_short | The role of interleukin-2 in the treatment of cancer patients |
| title_sort | the role of interleukin 2 in the treatment of cancer patients |
| topic | Oncology Immunology Oncology Interleukin 2 (DE-588)4162018-5 gnd Therapie (DE-588)4059798-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Oncology Immunology Oncology Interleukin 2 Therapie Krebs Medizin |
| url | https://doi.org/10.1007/978-94-011-1753-1 |
| work_keys_str_mv | AT wagstaffjohn theroleofinterleukin2inthetreatmentofcancerpatients |